Santen Pharmaceutical (SNPH.F) Stock Overview
Engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
SNPH.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Santen Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥9.51 |
| 52 Week High | JP¥11.45 |
| 52 Week Low | JP¥8.88 |
| Beta | 0.28 |
| 1 Month Change | 0% |
| 3 Month Change | -5.91% |
| 1 Year Change | n/a |
| 3 Year Change | 18.79% |
| 5 Year Change | -42.02% |
| Change since IPO | -41.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| SNPH.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.01% | -0.3% |
| 1Y | n/a | 30.2% | 15.4% |
Return vs Industry: Insufficient data to determine how SNPH.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SNPH.F performed against the US Market.
Price Volatility
| SNPH.F volatility | |
|---|---|
| SNPH.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SNPH.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SNPH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1890 | 3,849 | Takeshi Ito | www.santen.com/en |
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative filed for marketing approval for the treatment of glaucoma and ocular hypertension; and epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval to treat allergic conjunctivitis. The company also offers netarsudil mesylate/latanoprost, a fixed dose combination drug of a ROCK inhibitor and a prostaglandin F2a derivative which is in phase III clinical trial for the treatment of glaucoma and ocular hypertension; and sepetaprost, a prostaglandin analogue eye drop drug that is in phase III clinical trials for the treatment of glaucoma and ocular hypertension.
Santen Pharmaceutical Co., Ltd. Fundamentals Summary
| SNPH.F fundamental statistics | |
|---|---|
| Market cap | US$3.37b |
| Earnings (TTM) | US$198.72m |
| Revenue (TTM) | US$1.84b |
Is SNPH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNPH.F income statement (TTM) | |
|---|---|
| Revenue | JP¥291.48b |
| Cost of Revenue | JP¥126.15b |
| Gross Profit | JP¥165.33b |
| Other Expenses | JP¥133.92b |
| Earnings | JP¥31.41b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 05, 2026
| Earnings per share (EPS) | 104.08 |
| Gross Margin | 56.72% |
| Net Profit Margin | 10.78% |
| Debt/Equity Ratio | 0% |
How did SNPH.F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/18 07:13 |
| End of Day Share Price | 2025/11/25 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Santen Pharmaceutical Co., Ltd. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |